Pranabananda Dutta to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Pranabananda Dutta has written about Drug Resistance, Neoplasm.
Connection Strength
0.258
-
Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141.
Score: 0.146
-
Mookerjee A, Mookerjee Basu J, Dutta P, Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4339-49.
Score: 0.060
-
Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019 02 08; 12(1):32.
Score: 0.036
-
Mookerjee A, Basu JM, Majumder S, Chatterjee S, Panda GS, Dutta P, Pal S, Mukherjee P, Efferth T, Roy S, Choudhuri SK. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer. 2006 Nov 15; 6:267.
Score: 0.015